Fig. 5.
Association between adherence to NCCN-recommended by type of first-line therapy and risk of treatment discontinuationa among advanced non-small-cell lung cancer (aNSCLC) patients (n = 15,898). Flatiron Health, 2011–2019. CI confidence interval, HR hazard ratio. Reference group was non-adherent patients. aTime from start to discontinuation of first-line treatment; patients who met any of the following are considered as having their first-line treatment discontinued (event): 1. Advanced to a new line of therapy; 2. Not advanced to a new line of therapy, but has a recorded date of death; 3. Not advanced to a new line of therapy and has no recorded date of death, but has evidence of structured activity more than 120 days after the last drug episode within the first line. **Adjusted for age at first-line therapy start, sex, stage at initial NSCLC diagnosis, smoking status. ***Immunotherapy and targeted therapy may have been administered alone or in combination with chemotherapy